RNXT vs. CHRS, VXRT, OPTN, ANIX, ADVM, FATE, VOR, BDTX, OCX, and SNTI
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Coherus BioSciences (CHRS), Vaxart (VXRT), OptiNose (OPTN), Anixa Biosciences (ANIX), Adverum Biotechnologies (ADVM), Fate Therapeutics (FATE), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), OncoCyte (OCX), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry.
RenovoRx vs.
Coherus BioSciences (NASDAQ:CHRS) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Coherus BioSciences received 438 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 65.36% of users gave Coherus BioSciences an outperform vote while only 52.38% of users gave RenovoRx an outperform vote.
RenovoRx has lower revenue, but higher earnings than Coherus BioSciences. RenovoRx is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 7.6% of Coherus BioSciences shares are held by company insiders. Comparatively, 7.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Coherus BioSciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Coherus BioSciences currently has a consensus price target of $5.38, suggesting a potential upside of 560.32%. RenovoRx has a consensus price target of $6.00, suggesting a potential upside of 545.16%. Given Coherus BioSciences' higher probable upside, equities analysts clearly believe Coherus BioSciences is more favorable than RenovoRx.
RenovoRx has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat RenovoRx's return on equity.
In the previous week, RenovoRx had 7 more articles in the media than Coherus BioSciences. MarketBeat recorded 10 mentions for RenovoRx and 3 mentions for Coherus BioSciences. RenovoRx's average media sentiment score of 0.23 beat Coherus BioSciences' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.
Summary
Coherus BioSciences beats RenovoRx on 10 of the 17 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
This page (NASDAQ:RNXT) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy RNXT Stock Free RNXT Stock Alerts